Scholarlink

Due to their distinctive features—such as selective action and the ability to enable targeted drug delivery—nanoparticles (NPs) offer promising opportunities to enhance the effectiveness of diagnostics and therapies for a wide range of diseases, especially cancer. Numerous studies on the biological properties of silver nanoparticles (AgNPs) and iron oxide nanoparticles (IONPs) highlight their potential for biomedical applications that require a high degree of biocompatibility. Moreover, the use of green synthesis methods, resulting in the formation of biocompatible biogenic nanoparticles, further expands the scope of their research. The aim of this study was to perform a comparative evaluation of the anticancer potential of biogenic silver and iron oxide nanoparticles relative to an established anticancer drug, using the breast carcinoma cell line ZR-75 (ATCC). The results of the study revealed that biogenic Fe₃O₄ nanoparticles exhibited no cytotoxicity, demonstrating high biocompatibility and potential as drug delivery carriers. In contrast, AgNPs showed a pronounced dose-dependent antitumor ef-fect (IC50–2.6 μg/well), which was not attributed to the action of the stabilizing agent Ocimum araratum. When combined with the anticancer drug, the complex exhibited an IC50 of 5.3 μg/well. AgNPs appear to be promising agents for further investigation of their antitumor activity profile and mechanisms of action, while Fe₃O₄ nanoparticles, due to their absolute biocompatibility, can be explored as potential drug delivery systems.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Antitumor Potential of Biogenic Iron Oxide (Fe₃O₄) and Silver Nanoparticles, As Well As Complex with 5-Fluorouracil, Against the ZR-75 Human Breast Carcinoma Cell Line

  • 会议论文

  • 发表日期：

    2025年

查看全文
  • Juleta Tumoyan,
  • Shushanik Kazaryan,
  • Seda Oganian,
  • Ashkhen Hovhannisyan

摘要

Due to their distinctive features—such as selective action and the ability to enable targeted drug delivery—nanoparticles (NPs) offer promising opportunities to enhance the effectiveness of diagnostics and therapies for a wide range of diseases, especially cancer. Numerous studies on the biological properties of silver nanoparticles (AgNPs) and iron oxide nanoparticles (IONPs) highlight their potential for biomedical applications that require a high degree of biocompatibility. Moreover, the use of green synthesis methods, resulting in the formation of biocompatible biogenic nanoparticles, further expands the scope of their research. The aim of this study was to perform a comparative evaluation of the anticancer potential of biogenic silver and iron oxide nanoparticles relative to an established anticancer drug, using the breast carcinoma cell line ZR-75 (ATCC). The results of the study revealed that biogenic Fe₃O₄ nanoparticles exhibited no cytotoxicity, demonstrating high biocompatibility and potential as drug delivery carriers. In contrast, AgNPs showed a pronounced dose-dependent antitumor ef-fect (IC50–2.6 μg/well), which was not attributed to the action of the stabilizing agent Ocimum araratum. When combined with the anticancer drug, the complex exhibited an IC50 of 5.3 μg/well. AgNPs appear to be promising agents for further investigation of their antitumor activity profile and mechanisms of action, while Fe₃O₄ nanoparticles, due to their absolute biocompatibility, can be explored as potential drug delivery systems.